Quan Anh Vu

Plus aucun poste en cours

Fortune : 195 802 $ au 30/04/2024

52 ans

Health Technology

Consumer Services

Finance

Anciens postes connus de Quan Anh Vu

Sociétés	Poste	Début	Fin
OCUGEN, INC.	Comptroller/Controller/Auditor	10/03/2023	14/08/2023
	Directeur Financier/CFO	06/03/2023	14/08/2023
	Corporate Officer/Principal	01/02/2023	06/03/2023
180 LIFE SCIENCES CORP.	Directeur des opérations	29/10/2021	18/01/2023
Solganick & Co., Inc.	Corporate Officer/Principal	01/09/2019	01/10/2021
Baleena Bioscience, Inc.	Corporate Officer/Principal	01/04/2021	01/10/2021
OPIANT PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/09/2016	01/08/2019

University of California, Los Angeles

Undergraduate Degree

Internationale

Etats-Unis	6
	2

Opérationnelle

Corporate Officer/Principal	4
Undergraduate Degree	1
Chief Operating Officer	1

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
OCUGEN, INC.	Health Technology
180 LIFE SCIENCES CORP.	Health Technology

Entreprise privées	3
Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA.	Health Technology
Solganick & Co., Inc.	Finance
Baleena Bioscience, Inc.